(Q38492121)

3 September 2017

0 references

1 reference

title

Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials (English)

1 reference

3 September 2017

1 reference

1 reference

1 reference

J Li

1

1 reference

3 September 2017

L Zhou

series ordinal

2

1 reference

3 September 2017

X Chen

series ordinal

3

1 reference

3 September 2017

Y Ba

series ordinal

4

1 reference

3 September 2017

publication date

20 May 2015

1 reference

Clinical and Translational Oncology

3 September 2017

published in

1 reference

3 September 2017

volume

17

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

673-683

1 reference

3 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Primary ovarian cancer chemotherapy: current standards of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Role of vascular endothelial growth factor in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Bias, prevalence and kappa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Big costs for little gain in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1293-Z

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

21 January 2018

1 reference

12 December 2020

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

1 reference

12 December 2020

The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

12 December 2020

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

1 reference

12 December 2020

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

12 December 2020

Anti-angiogenesis: new concept for therapy of solid tumors

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

12 December 2020

Ten-year relative survival for epithelial ovarian cancer

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

10.1007/S12094-015-1293-Z

Identifiers

DOI

1 reference

3 September 2017

1 reference